165 related articles for article (PubMed ID: 20099263)
1. QSAR modeling of a set of pyrazinoate esters as antituberculosis prodrugs.
Fernandes JP; Pasqualoto KF; Felli VM; Ferreira EI; Brandt CA
Arch Pharm (Weinheim); 2010 Feb; 343(2):91-7. PubMed ID: 20099263
[TBL] [Abstract][Full Text] [Related]
2. Lipophilic pyrazinoic acid amide and ester prodrugs stability, activation and activity against M. tuberculosis.
Simões MF; Valente E; Gómez MJ; Anes E; Constantino L
Eur J Pharm Sci; 2009 Jun; 37(3-4):257-63. PubMed ID: 19491013
[TBL] [Abstract][Full Text] [Related]
3. Esters of Pyrazinoic Acid Are Active against Pyrazinamide-Resistant Strains of Mycobacterium tuberculosis and Other Naturally Resistant Mycobacteria In Vitro and Ex Vivo within Macrophages.
Pires D; Valente E; Simões MF; Carmo N; Testa B; Constantino L; Anes E
Antimicrob Agents Chemother; 2015 Dec; 59(12):7693-9. PubMed ID: 26438493
[TBL] [Abstract][Full Text] [Related]
4. Quantitative structure-activity relationships for the in vitro antimycobacterial activity of pyrazinoic acid esters.
Bergmann KE; Cynamon MH; Welch JT
J Med Chem; 1996 Aug; 39(17):3394-400. PubMed ID: 8765523
[TBL] [Abstract][Full Text] [Related]
5. Antimycobacterial activity of pyrazinoate prodrugs in replicating and non-replicating Mycobacterium tuberculosis.
Segretti ND; Simões CK; Corrêa MF; Felli VMA; Miyata M; Cho SH; Franzblau SG; Fernandes JPDS
Tuberculosis (Edinb); 2016 Jul; 99():11-16. PubMed ID: 27449999
[TBL] [Abstract][Full Text] [Related]
6. Antimycobacterial activity of a series of pyrazinoic acid esters.
Cynamon MH; Klemens SP; Chou TS; Gimi RH; Welch JT
J Med Chem; 1992 Apr; 35(7):1212-5. PubMed ID: 1560435
[TBL] [Abstract][Full Text] [Related]
7. Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis.
Zimhony O; Cox JS; Welch JT; Vilchèze C; Jacobs WR
Nat Med; 2000 Sep; 6(9):1043-7. PubMed ID: 10973326
[TBL] [Abstract][Full Text] [Related]
8. Potential tuberculostatic agent: micelle-forming pyrazinamide prodrug.
Silva M; Ricelli NL; El Seoud O; Valentim CS; Ferreira AG; Sato DN; Leite CQ; Ferreira EI
Arch Pharm (Weinheim); 2006 Jun; 339(6):283-90. PubMed ID: 16688684
[TBL] [Abstract][Full Text] [Related]
9. Activity of n-propyl pyrazinoate against pyrazinamide-resistant Mycobacterium tuberculosis: investigations into mechanism of action of and mechanism of resistance to pyrazinamide.
Speirs RJ; Welch JT; Cynamon MH
Antimicrob Agents Chemother; 1995 Jun; 39(6):1269-71. PubMed ID: 7574514
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, anti-tuberculosis activity, and 3D-QSAR study of 4-(adamantan-1-yl)-2-substituted quinolines.
Nayyar A; Monga V; Malde A; Coutinho E; Jain R
Bioorg Med Chem; 2007 Jan; 15(2):626-40. PubMed ID: 17107805
[TBL] [Abstract][Full Text] [Related]
11. Salicylanilide pyrazinoates inhibit in vitro multidrug-resistant Mycobacterium tuberculosis strains, atypical mycobacteria and isocitrate lyase.
Krátký M; Vinšová J; Novotná E; Stolaříková J
Eur J Pharm Sci; 2014 Mar; 53():1-9. PubMed ID: 24333643
[TBL] [Abstract][Full Text] [Related]
12. Iron enhances the antituberculous activity of pyrazinamide.
Somoskovi A; Wade MM; Sun Z; Zhang Y
J Antimicrob Chemother; 2004 Feb; 53(2):192-6. PubMed ID: 14729751
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and antimycobacterial evaluation of N-substituted 3-aminopyrazine-2,5-dicarbonitriles.
Zitko J; Jampílek J; Dobrovolný L; Svobodová M; Kuneš J; Doležal M
Bioorg Med Chem Lett; 2012 Feb; 22(4):1598-601. PubMed ID: 22281187
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and antimycobacterial activity of N'-[(E)-(monosubstituted-benzylidene)]-2-pyrazinecarbohydrazide derivatives.
Vergara FM; Lima CH; Henriques Md; Candéa AL; Lourenço MC; Ferreira Mde L; Kaiser CR; de Souza MV
Eur J Med Chem; 2009 Dec; 44(12):4954-9. PubMed ID: 19765866
[TBL] [Abstract][Full Text] [Related]
15. Pyrazinamide and Pyrazinoic Acid Derivatives Directed to Mycobacterial Enzymes Against Tuberculosis.
Corrêa MF; Fernandes JP
Curr Protein Pept Sci; 2016; 17(3):213-9. PubMed ID: 26427385
[TBL] [Abstract][Full Text] [Related]
16. Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide.
Zhang Y; Scorpio A; Nikaido H; Sun Z
J Bacteriol; 1999 Apr; 181(7):2044-9. PubMed ID: 10094680
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Multiple Linear Regressions and Neural Networks based QSAR models for the design of new antitubercular compounds.
Ventura C; Latino DA; Martins F
Eur J Med Chem; 2013; 70():831-45. PubMed ID: 24246731
[TBL] [Abstract][Full Text] [Related]
18. Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid.
Zhang Y; Wade MM; Scorpio A; Zhang H; Sun Z
J Antimicrob Chemother; 2003 Nov; 52(5):790-5. PubMed ID: 14563891
[TBL] [Abstract][Full Text] [Related]
19. Preparation and in vitro evaluation of benzylsulfanyl benzoxazole derivatives as potential antituberculosis agents.
Klimesová V; Kocí J; Waisser K; Kaustová J; Möllmann U
Eur J Med Chem; 2009 May; 44(5):2286-93. PubMed ID: 18694614
[TBL] [Abstract][Full Text] [Related]
20. Rational design and 3D-pharmacophore mapping of 5'-thiourea-substituted alpha-thymidine analogues as mycobacterial TMPK inhibitors.
Andrade CH; Pasqualoto KF; Ferreira EI; Hopfinger AJ
J Chem Inf Model; 2009 Apr; 49(4):1070-8. PubMed ID: 19296716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]